JP2009530413A5 - - Google Patents

Download PDF

Info

Publication number
JP2009530413A5
JP2009530413A5 JP2009501667A JP2009501667A JP2009530413A5 JP 2009530413 A5 JP2009530413 A5 JP 2009530413A5 JP 2009501667 A JP2009501667 A JP 2009501667A JP 2009501667 A JP2009501667 A JP 2009501667A JP 2009530413 A5 JP2009530413 A5 JP 2009530413A5
Authority
JP
Japan
Prior art keywords
optionally substituted
composition
methyl
adenosine receptor
trihydropurine
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Granted
Application number
JP2009501667A
Other languages
English (en)
Japanese (ja)
Other versions
JP5250848B2 (ja
JP2009530413A (ja
Filing date
Publication date
Application filed filed Critical
Priority claimed from PCT/US2007/064182 external-priority patent/WO2007109547A2/en
Publication of JP2009530413A publication Critical patent/JP2009530413A/ja
Publication of JP2009530413A5 publication Critical patent/JP2009530413A5/ja
Application granted granted Critical
Publication of JP5250848B2 publication Critical patent/JP5250848B2/ja
Active legal-status Critical Current
Anticipated expiration legal-status Critical

Links

JP2009501667A 2006-03-17 2007-03-16 Ａ２ｂアデノシン受容体拮抗物質を用いる肝疾患の予防および処置の方法 Active JP5250848B2 (ja)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
US78357506P 2006-03-17 2006-03-17
US60/783,575 2006-03-17
PCT/US2007/064182 WO2007109547A2 (en) 2006-03-17 2007-03-16 Method of preventing and treating hepatic disease using a2b adenosine receptor antagonists

Related Child Applications (1)

Application Number Title Priority Date Filing Date
JP2012268193A Division JP2013049719A (ja) 2006-03-17 2012-12-07 Ａ２ｂアデノシン受容体拮抗物質を用いる肝疾患の予防および処置の方法

Publications (3)

Publication Number Publication Date
JP2009530413A JP2009530413A (ja) 2009-08-27
JP2009530413A5 true JP2009530413A5 (enExample) 2011-03-03
JP5250848B2 JP5250848B2 (ja) 2013-07-31

Family

ID=38514256

Family Applications (2)

Application Number Title Priority Date Filing Date
JP2009501667A Active JP5250848B2 (ja) 2006-03-17 2007-03-16 Ａ２ｂアデノシン受容体拮抗物質を用いる肝疾患の予防および処置の方法
JP2012268193A Pending JP2013049719A (ja) 2006-03-17 2012-12-07 Ａ２ｂアデノシン受容体拮抗物質を用いる肝疾患の予防および処置の方法

Family Applications After (1)

Application Number Title Priority Date Filing Date
JP2012268193A Pending JP2013049719A (ja) 2006-03-17 2012-12-07 Ａ２ｂアデノシン受容体拮抗物質を用いる肝疾患の予防および処置の方法

Country Status (14)

Country Link
US (4) US7795268B2 (enExample)
EP (1) EP1996201A2 (enExample)
JP (2) JP5250848B2 (enExample)
KR (1) KR101428113B1 (enExample)
CN (1) CN101405003B (enExample)
AU (1) AU2007227021B2 (enExample)
CA (2) CA2849661A1 (enExample)
IL (1) IL194158A0 (enExample)
MX (1) MX2008011828A (enExample)
NO (1) NO20083968L (enExample)
NZ (1) NZ571324A (enExample)
RU (1) RU2457842C2 (enExample)
WO (1) WO2007109547A2 (enExample)
ZA (1) ZA200807894B (enExample)

Families Citing this family (33)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US7317017B2 (en) * 2002-11-08 2008-01-08 Cv Therapeutics, Inc. A2B adenosine receptor antagonists
US20080318983A1 (en) * 2001-11-09 2008-12-25 Rao Kalla A2b adenosine receptor antagonists
US20080194593A1 (en) * 2001-11-09 2008-08-14 Rao Kalla A2b adenosine receptor antagonists
DK1658291T3 (da) * 2003-08-25 2013-10-28 Dogwood Pharmaceuticals Inc Substituerede 8-heteroaryl xanthiner
RU2391103C2 (ru) 2004-10-15 2010-06-10 Си Ви Терапьютикс, Инк. Способ предупреждения и лечения ремоделирования дыхательных путей и воспаления легких с применением антагонистов аденозиновых рецепторов a2b
WO2006091936A2 (en) * 2005-02-25 2006-08-31 Adenosine Therapeutics, Llc Methods for the synthesis of unsymmetrical cycloalkyl substituted xanthines
WO2006091897A2 (en) * 2005-02-25 2006-08-31 Adenosine Therapeutics, Llc Derivatives of 8-substituted xanthines
WO2006091898A2 (en) * 2005-02-25 2006-08-31 Adenosine Therapeutics, Llc Pyrazolyl substituted xanthines
CN101198608B (zh) * 2005-06-16 2011-04-27 吉利德帕洛阿尔托股份有限公司 A2b腺苷受体拮抗剂的前药
CA2849661A1 (en) 2006-03-17 2007-09-27 Gilead Sciences, Inc. Method of preventing and treating hepatic disease using a2b adenosine receptor antagonists
US7884100B2 (en) * 2006-06-16 2011-02-08 Pgxhealth, Llc Substituted 8-[6-amino-3-pyridyl]xanthines
JP2009541436A (ja) * 2006-06-27 2009-11-26 ビオヴィトルム・アクチボラゲット（プブリクト） 治療用化合物
US7767685B2 (en) * 2006-06-29 2010-08-03 King Pharmaceuticals Research And Development, Inc. Adenosine A2B receptor antagonists
EP2217233B1 (en) * 2007-10-26 2018-08-08 New York University School of Medicine Methods and compositions for treating hepatic diseases
US7875608B2 (en) * 2007-12-17 2011-01-25 Thompson Robert D Substituted 8-[6-amino-3pyridyl]xanthines
BRPI0909157A2 (pt) 2008-03-26 2015-11-24 Advinus Therapeutics Private Ltd compostos heterocíclicos como antagonistas de receptores de adenosina
JP5765239B2 (ja) 2009-03-13 2015-08-19 アドヴィナス・セラピューティックス・リミテッド 置換縮合ピリミジン化合物
JP5843778B2 (ja) 2009-11-09 2016-01-13 アドヴィナス・セラピューティックス・リミテッド 置換縮合ピリミジン化合物、その調製およびその使用
US8940751B2 (en) 2010-09-13 2015-01-27 Advinus Therapeutics Private Limited Purine compounds as prodrugs of A2B adenosine receptor antagonists, their process and medicinal applications
US20140142113A1 (en) * 2012-11-09 2014-05-22 Michael W. Burnet Method of treating inflammatory diseases using adenosine 2b receptor antagonists
US10583102B2 (en) 2014-10-06 2020-03-10 The Johns Hopkins University Targeting liver nuclear receptors as a treatment for wilson disease
KR101666605B1 (ko) 2015-02-13 2016-10-18 한국과학기술원 TNP(N2-(m-Trifluorobenzyl), N6-(p-nitrobenzyl)purine)를 유효성분으로 함유하는 아세트아미노펜 유래 간 독성 예방 및 치료용 조성물
WO2016129760A1 (ko) * 2015-02-13 2016-08-18 한국과학기술원 Tnp(n2-(m-trifluorobenzyl), n6-(p-nitrobenzyl)purine)를 유효성분으로 함유하는 아세트아미노펜 유래 간 독성 예방 및 치료용 조성물
EP3900786A1 (en) 2015-10-29 2021-10-27 CLS Therapeutics Limited Use of dnase to improve safety and efficacy of cancer radiotherapy or chemotherapy
JP7174408B2 (ja) 2016-02-10 2022-11-17 ウェイク・フォレスト・ユニヴァーシティ・ヘルス・サイエンシズ 肝線維症のモデル系ならびにその作製および使用方法
KR101709307B1 (ko) * 2016-10-31 2017-02-23 퓨쳐메디신 주식회사 아데노신 유도체를 포함하는 비알콜성 지방간염, 간섬유증 및 간경변증 예방 및 치료용 약학적 조성물
JP7189155B2 (ja) * 2017-05-17 2022-12-13 アーカス バイオサイエンシズ インコーポレイティド 癌関連障害の治療のためのキナゾリン－ピラゾール誘導体
AU2018325451A1 (en) * 2017-08-31 2020-03-05 Corvus Pharmaceuticals, Inc. Compounds and methods for modulating adenosine A2B receptor and adenosine A2A receptor
IL277144B2 (en) * 2018-03-05 2024-06-01 Teon Therapeutics Inc Adenosine receptor antagonists and uses thereof
GB201804922D0 (en) 2018-03-27 2018-05-09 Ucl Business Plc Traatment
WO2020023846A1 (en) 2018-07-27 2020-01-30 Arcus Biosciences, Inc. Pyridone a2r antagonists
CN111686239B (zh) * 2019-03-11 2021-12-24 中国科学院微生物研究所 抗真菌化合物的应用
US11116737B1 (en) 2020-04-10 2021-09-14 University Of Georgia Research Foundation, Inc. Methods of using probenecid for treatment of coronavirus infections

Family Cites Families (9)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
GB0028383D0 (en) * 2000-11-21 2001-01-03 Novartis Ag Organic compounds
ATE520694T1 (de) * 2001-11-09 2011-09-15 Gilead Palo Alto Inc A2b-adenosinrezeptorantagonisten
US7125993B2 (en) * 2001-11-09 2006-10-24 Cv Therapeutics, Inc. A2B adenosine receptor antagonists
ES2208063B1 (es) * 2002-04-01 2005-10-01 Almirall Prodesfarma, S.A. Nuevos derivados de la 4-(pirrolopirimidin-6-il)bencenosulfonamida.
US7064204B2 (en) * 2002-05-30 2006-06-20 King Pharmacueticals Reserch And Development, Inc. Pharmaceutically active compounds having a tricyclic pyrazolotriazolopyrimidine ring structure and methods of use
WO2004086052A2 (en) 2003-03-28 2004-10-07 Bayer Healthcare Ag Diagnostics and therapeutics for diseases associated with g-protein-coupled receptor adenosine a2b (adora2b)
GB0401336D0 (en) * 2004-01-21 2004-02-25 Novartis Ag Organic compounds
CN101198608B (zh) * 2005-06-16 2011-04-27 吉利德帕洛阿尔托股份有限公司 A2b腺苷受体拮抗剂的前药
CA2849661A1 (en) 2006-03-17 2007-09-27 Gilead Sciences, Inc. Method of preventing and treating hepatic disease using a2b adenosine receptor antagonists

Similar Documents

Publication Publication Date Title
JP2009530413A5 (enExample)
RU2008137279A (ru) Способ предотвращения и лечения болезни печени с использованием антагонистов рецептора аденозина а2в
CN103096881B (zh) 含有具有不愉快味道的药物的膜制剂
JP2018507914A5 (enExample)
JP2018514534A5 (enExample)
JP2010530376A5 (enExample)
US20190216779A1 (en) Use of neurokinin-1 antagonists to treat a variety of pruritic conditions
JP2007536311A5 (enExample)
JP2009102342A5 (enExample)
FI3735295T3 (fi) Parannetut peptidilääkkeet nashin ja muiden sairauksien hoitoon
JP2008540672A (ja) 病状に起因する性的機能不全の治療方法
JP2015524444A5 (enExample)
JP2019503365A5 (enExample)
JP2012520866A5 (enExample)
HRP20211032T1 (hr) Postupci za uporabu agonista fxr
JP2006523216A5 (enExample)
JP2010503695A5 (enExample)
IL314360A (en) Method of synthesizing thyroid hormone analogs and polymorphs thereof
TWI455723B (zh) 納曲酮及安非他酮於治療超重或肥胖病患之用途
SI2529622T1 (en) Inhibitors of bruton's tyrosine kinase
WO2010121128A3 (en) Compositions and methods for treating or inhibiting liver injury
NZ582089A (en) Antiviral Combination of elvitegravir, lopinavir and optionally ritonavir
NZ625592A (en) Compositions and methods for the treatment of hepatic diseases and disorders
ES2973583T3 (es) Regímenes de administración asociados a las formulaciones inyectables de paliperidona de liberación prolongada
JP2015517523A5 (enExample)